Chemical Watch: November 2013

The German Federal Institute for Risk Assessment (BfR), with support from the European Commission, is organising a workshop on the setting of maximum residue limits (MRLs) for biocides.

The event, which will be held next March, aims to discuss some open questions regarding an EU-wide procedure for setting MRLs, according to a BfR representative at the Biocides 2013 conference in Vienna this week.

Subjects to be discussed include formats to be used and whether MRL applications should be submitted before or after the biocidal product application.


 Infection Control: November 2013

The U.S. Food and Drug Administration (FDA) is requesting label and packaging changes to enhance the safe use of certain over-the-counter (OTC) topical antiseptic products.

This request is the result of FDA's ongoing evaluation of infrequent but continuing reports of infections resulting from antiseptic products labelled for preoperative or pre-injection skin preparation. These products are marketed as solutions, swabs, pads saturated with a solution, and applicators containing a solution.

Commonly used products contain isopropyl or ethyl alcohol, povidone iodine, poloxamer-iodine, benzalkonium chloride, benzethonium chloride, or chlorhexidine gluconate as a single agent or in combination with alcohol.

FDA is also asking manufacturers to voluntarily revise the product labels for topical antiseptics to indicate whether the drug is manufactured as a sterile or nonsterile product. FDA believes this will assist healthcare professionals in making informed decisions about using these products. Topical antiseptics are not required to be manufactured as sterile and so may become contaminated with bacteria during manufacturing.

Labelling stating a product is sterile means it was treated with a process during  manufacturing to eliminate all potential microorganisms. When used properly, topical antiseptics are safe and effective products to reduce the number of bacteria on patients' skin prior to surgery or injections.

However, most often, contamination of topical antiseptics occurs when organisms are introduced into the product by users. Therefore, healthcare professionals and patients should follow all label directions to decrease the chances of infection.


 Oil & Gas: November 2013

BWA Water Additives will be showcasing its broad-spectrum EPA-approved biocides, Bellacide® 355 and Bellacide® 301 that improve microbiological performance while reducing total costs at the IWC conference.

"Our customers are finding that Bellacide® 355 is a great 'clean up' biocide for out of control or difficult to treat cooling towers, whereas Bellacide® 301 is a more economical long-term 'keep clean' biocide," says Nozi Hamidi, BWA VP Marketing. "With our new biocides, we have been able to help some customers achieve more than 50% savings compared to isothiazolone."


 Clean room Technology: November 2013

PurThread Technologies and Eastman Kodak are collaborating to bring Kodak's antimicrobial agent to the high performance and medical textile markets. PurThread has obtained a globally exclusive agreement to embed Kodak's antimicrobial agent into textile materials.

PurThread's process embeds Kodak's antimicrobial agent into synthetic fibres, before the fibre is spun into yarn and woven into fabric, ensuring that the antimicrobial effects of the fabric are uniform and constant throughout the life of the product. This proprietary antimicrobial technology is derived from Kodak's expertise related to the production of photosensitive materials for use in photographic products.

Currently, PurThread's product line includes healthcare textiles, such as medical scrubs, lab coats, privacy curtains and linens, as well as fitness apparel.

'We are extremely pleased with the efficacy of Kodak's antimicrobial agent and their stewardship in the development of our textile technology,' said Lisa Grimes, President and CEO of PurThread Technologies. 'With Kodak's superior technology, our products have delivered consistently high marks for effectiveness in protecting fabrics from odour-causing organisms. We look forward to continuing research into how our textile products can play a part in comprehensive infection control strategies.'

'The antimicrobial technology sector is an exciting new venture for Kodak,' said Tom McHugh, General Manager, Materials Technology and Business Development for Kodak's Digital Printing & Enterprise segment. 'Because of PurThread's unique manufacturing process and expertise in the textile industry, we are delighted to be working with them to bring to market products using our propriety materials and technology. We look forward to building on this relationship with PurThread.'


 Compounding World: October 2013

Noble Biomaterials, the global leader in bacterial management solutions and manufacturer of X-STATIC® and X-STATIC®XT2 technologies, announces it has achieved bluesign® system partnership after undergoing stringent bluesign® screening.

The bluesign® system partnership will assure manufacturers, retailers and consumers that the production of X-STATIC® and XT2 fibers is environmentally friendly and committed to the contemporary sustainable textile requirements set forth by the bluesign® system.

The independent bluesign® system follows a unique approach to minimize environmental impact throughout the production process. Instead of testing finished products, the bluesign® system is applied where the production begins. On-site visits of independent experts certify that companies' production processes meet five necessary requirements: resource productivity, air emission, occupational health and safety, water emission and consumer safety. As bluesign® technologies performs regular audits, system partners regularly report their progress and must meet improvement goals to maintain their status.

"Consumers today expect athletic apparel to deliver maximum performance while ensuring they're made using eco-friendly materials," said Jeff Keane, CEO, Noble Biomaterials. "Our bluesign® system partner status allows us to work with brands that require anti-odor technologies that are environmentally sustainable."

About Noble Biomaterials X-STATIC®

X-STATIC® is a registered trademark of Noble Fiber Technologies, LLC. Headquartered in Scranton, PA, Noble Biomaterials, Inc. is a global leader in bacterial management solutions. The company develops, manufactures, sells and markets advanced antimicrobial technologies designed to manage all forms of bacterial contamination. It has more than 200 global licensees for products in the medical, defence, industrial and consumer markets and the company's headquarters and manufacturing facilities are located in Scranton, PA, with global offices in Europe, Asia and South America. www.x-staticperformance.com